Acute Kidney Injury and Bisphosphonate Use in Cancer: A Report From the Research on Adverse Drug Events and Reports (RADAR) Project
- 1 March 2013
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 9 (2) , 101-106
Abstract
Analysis of bisphosphonate-associated acute kidney injury reports for cancer cases within FDA's Adverse Events and Reporting System failed to demonstrate a significant safety signal, an unexpected finding given prior preclinical and clinical findings that suggested a causal association between BPs and AKI.Keywords
This publication has 64 references indexed in Scilit:
- American Society of Clinical Oncology Clinical Practice Guideline Update: Recommendations on the Role of Bone-Modifying Agents in Metastatic Breast CancerJournal of Oncology Practice, 2011
- Quality of Reporting of Serious Adverse Drug Events to an Institutional Review Board: A Case Study with the Novel Cancer Agent, Imatinib MesylateClinical Cancer Research, 2009
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerNew England Journal of Medicine, 2009
- Correlation between the AKI classification and outcomeCritical Care, 2008
- Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injuryCritical Care, 2007
- Quantitative Methods in PharmacovigilanceDrug Safety, 2003
- Adverse Effects of BisphosphonatesDrug Safety, 1996
- Efficacy of Pamidronate in Breast Cancer with Bone Metastases: A Randomized Double-Blind Placebo Controlled Multicenter StudyActa Oncologica, 1996
- ClodronateDrugs, 1994
- Disposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD), in rats and miceToxicology, 1990